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patients, the most commonly reported challenges included 
delayed care (37%), long-term disability (33%), and confu-
sion or unanswered questions about chordoma (28%). For 
caregivers, grief (55%), delayed diagnosis (47%), and diffi-
culty helping the patient cope with his or her disease (45%) 
were most common.
Conclusions Our study findings suggest a high symp-
tom burden and life challenges among chordoma patients 
and their caregivers. This study provides preliminary, lim-
ited estimates of the prevalence of a wide range of self-
reported symptoms and challenges that will inform the 
assessment of patient-reported outcomes in future clinical 
trials and help clinicians better manage chordoma patients’ 
symptoms.
Keywords Chordoma · Symptom burden · Patient-
reported outcomes · Quality of life
Introduction
Chordoma is a rare bone cancer that accounts for 1–4% of 
all bone malignancies [1]. Chordoma is a highly morbid 
and potentially fatal disease that involves complex medi-
cal decisions, and the low incidence of chordoma creates 
challenges for tailoring care. Chordoma tumors are thought 
to be derived from notochord remnants that may persist 
anywhere along the axial skeleton [1, 2]. Chordomas are 
generally slow growing, chemotherapy-, and radiotherapy-
resistant tumors that are locally invasive [1].
Population-based studies using the Surveillance, Epide-
miology, and End Results (SEER) database estimate the 
age-adjusted incidence of all chordoma cases to be 0·08 to 
0.089 per 100,000. Chordoma is more common in men and 
the incidence is highest among 50–60 years of age [1–4]. 
Abstract 
Purpose This study aims to characterize the symptom 
burden and life challenges that chordoma patients and their 
caregivers experience.
Methods In this cross-sectional study, we analyzed data 
from the Chordoma Foundation online community survey 
conducted in 2014. Frequency counts and percentages were 
calculated to determine the prevalence of self-reported 
symptoms and life challenges in the sample. We used Fish-
er’s exact test to compare self-reported symptoms among 
subgroups with different disease status, tumor locations, 
and treatments received.
Results Among the survey participants, 358 identified 
themselves as chordoma patients and 202 as caregivers. 
The majority of the patients were over 45 years (72%), male 
(56%), educated beyond high school degree (87%), and 
from North America (77%). Skull base was the most preva-
lent tumor location (40%). Chronic pain (35%) was the 
most commonly reported symptom followed by depression 
or severe anxiety (32%) and chronic fatigue (31%). Among 
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Chordoma is less frequent among patients younger than 40 
years and rarely affects children and adolescents (less than 
5% of all chordoma cases) [1]. The anatomic distribution 
of chordomas is almost equal among the skull base (32%), 
mobile spine (33%), and sacrum (29%) [1] Chordoma 
accounts for over 50% of primary sacral tumors [1] and less 
than 1% of all intracranial neoplasms [2].
Most studies estimate the survival of chordoma patients 
using data from the SEER database, showing a median 
overall survival of 7.8 years [4]. Surgery plus radiation 
therapy is estimated to increase the overall median sur-
vival time to 9.2 years. Age and treatment modality are 
significant determinants of patients’ survival [3]. Younger 
patients (aged <40 years) survive longer compared with 
older patients (10-year relative survival of 68% vs. 43%) 
[4]. Specifically, age >50 years is associated with an 
increase in mortality rate. The estimated age-standardized 
5-year, 10-year, and 20-year survival rates for patients 
diagnosed between 1973 and 2009 are 72, 48, and 31%, 
respectively [4]. Improved survival is seen over time with 
5-year survival rates of 48, 73, and 81% for the 1975–1984, 
1985–1994, and 1995–2004 cohorts, respectively [3]. 
Primary tumor site has not shown to influence chordoma 
patients’ survival [5, 6].
As chordoma patients survive longer, the importance of 
identifying determinants of health-related quality of life 
(HRQOL) in guiding comprehensive patient care increases 
[2]. Chordoma progresses slowly but continuously, affect-
ing multiple vital functions, which results in disability and 
death. As chordoma progresses, it affects patients’ physi-
cal, social, and mental wellbeing and increases the need 
for caregiver support [2]. However, symptom burden and 
other determinants of HRQOL remain poorly defined in 
patients with chordoma [2]. Improving HRQOL during and 
after treatment is a primary endpoint underlying clinical 
decision-making and the development of optimal treatment 
regimens for patients with chordoma [7]. A better under-
standing of the symptom burden and main challenges that 
chordoma patients and caregivers face will help clinicians 
and palliative care providers improve the quality of care for 
chordoma patients.
The number of clinical trials testing different interven-
tions for treating chordoma has significantly increased over 
the past few years [8]. Currently, three Phase 1, two Phase 
2, and one Phase 3 randomized clinical trials are in pro-
gress that assess the efficacy and safety of surgery, radio-
therapy, and medical therapy in treating chordoma patients 
[8]. Patient-reported outcomes (PROs), especially symp-
tom burden and functional status, are increasingly assessed 
in oncology clinical trials for approval and reimburse-
ment purposes [9]. Although challenges exist for assessing 
PROs for rare conditions like chordoma, many of the barri-
ers are inherent to studying rare diseases rather than PRO 
measurement itself, and the common barriers and solutions 
have been documented [10]. Information about the preva-
lence of the symptoms and other determinants of HRQOL 
in patients undergoing treatment for chordoma is essential 
for planning PRO assessment in a clinical trial. This infor-
mation supports the identification of the most relevant PRO 
endpoints and provides preliminary support of the content 
validity of PRO instruments [11].
This study aims to characterize the symptom burden 
and challenges to quality of life that chordoma patients and 
their caregivers experience.
Methods
Study design and setting
In this cross-sectional study, we analyzed data from a sur-
vey of the chordoma community conducted by the Chor-
doma Foundation to determine the prevalence of self-
reported symptoms experienced by chordoma patients and 
the chordoma-related life challenges that patients and their 
caregivers experience. The Chordoma Foundation (CF) is a 
global non-profit organization whose mission is to improve 
the lives of those affected by chordoma and lead the search 
for a cure. In 2014, the CF conducted an internet-based sur-
vey of the chordoma community to better define the needs 
and range of experiences of its constituents. At the time of 
the survey, the CF’s contact database included 950 self-
identified chordoma patients and 3,276 individuals iden-
tified as family members or friends of patients. In March 
2014, a link to the survey was emailed to all members of 
the foundation’s database, including both patients and car-
egivers. The survey was open to respondents until the end 
of June 2014.
Survey instrument
The domains of the survey include self-reported symptoms, 
chordoma-related life challenges, quality of care, and the 
role of the CF in serving the chordoma community world-
wide. The survey, written in English, contains 35 questions 
and takes approximately 19 minutes to complete. The CF 
developed the survey with input from members of the chor-
doma patient community, the moderators of the chordoma 
survivors Facebook group, and physicians who treat chor-
doma patients. The survey was constructed and adminis-
tered through Survey Monkey with branching logic direct-
ing patients and caregivers to answer questions relevant to 
their respective experiences with chordoma. The survey 
questionnaire is available in the electronic supplementary 
material.
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Statistical analysis
Due to a very small sample size of children respondents, 
the study analyses focus on respondents who were 18 years 
and older. Caregivers were defined as parents, spouse, or 
family members providing care to a patient with chordoma. 
The analysis of self-reported symptoms was limited to 
patient respondents because patients are the most reliable 
source of information regarding their symptoms [12]. The 
analysis of chordoma-related life challenges included data 
from both patient and caregiver respondents. Two sepa-
rate questions with slightly different response options were 
included in the survey for patients and caregivers about 
their experience with challenges that they face as a result of 
chordoma (patients) and caring for a patient with chordoma 
(caregivers).
Frequency counts and percentages were calculated to 
determine the prevalence of self-reported symptoms in the 
sample. Fisher’s exact test was used to compare the preva-
lence of a wide range of symptoms (Tables 3, 4, 5) in dif-
ferent subgroups. Associations were calculated between the 
most common symptoms reported and the following clini-
cal characteristics: location of tumor, disease status, and 
type of treatment received. The prevalence of chordoma-
related symptoms among subgroups with different tumor 
locations, disease status, and type of treatment received 
was tabulated. Data were analyzed using Stata software 
version 12 (StataCorp, College Station, TX), and p < 0.05 
was considered statistically significant.
Results
Study population
Between March and June 2014, 709 participants including 
chordoma patients (358), their family members (294), and 
friends and others (57) responded to the online CF commu-
nity survey (Table 1). Among family members, i.e., parents 
(31%), spouses (36%), and other family members (33%), 
202 participants identified themselves as a caregiver to a 
chordoma patient. The majority of the patient respondents 
were over 45 years (72%), male (56%), educated beyond 
high school degree (87%), and from North America (77%). 
Caregivers were predominantly over 45 years (62%), female 
(66%), educated beyond high school degree (86%), and 
from North America (74%). The skull base was the most 
common tumor location in our patient sample (40%) fol-
lowed by sacrococcygeal tumors (31%) and mobile spine, 
i.e., neck, mid back, and lower back (27%). The majority of 
patients reported either disease-free status, i.e., no evidence 
of tumor (41%) or stable local disease (28%). The major-
ity of patients reported receiving multiple therapies, i.e., a 
Table 1  Demographic characteristics of the chordoma patients and 
caregivers
Not reported: age (patient: 1, caregiver: 1); gender (p: 2, c: 1); educa-
tion (p: 1, c: 2); tumor location (p: 2, c: 5); current status of disease 
(p: 21, c: 67); treatment received (p: 28, c: 18)
a Reflects caregivers’ demographic characteristics (age, gender, edu-
cation, and region) and patients’ tumor location, current status of the 
disease, and treatment received reported by their caregiver
b Includes extra-axial, multifocal, or unknown
Age Patients 
(n = 358)
Caregivers 
(n = 202)a
No % No %
18–24 16 4 12 6
25–34 31 9 27 13
35–44 54 15 36 18
45–54 84 23 41 20
55–64 105 29 52 26
65–74 52 15 26 13
74 or older 15 4 7 3
Gender
 Male 199 56 68 34
 Female 157 44 133 66
Education
 Some high school or less 8 2 8 4
 High school graduate or GED 36 10 19 9
 Vocational college or some college 99 28 35 17
 College degree 111 31 73 36
 Professional or graduate degree 103 29 65 32
Region
 North America 275 77 149 74
 Europe 59 16 32 16
 South America 7 2 5 3
 Asia 8 2 9 5
 Australia and New Zealand 6 2 5 3
 Africa 3 1 2 1.0
Tumor location
 Skull base 144 40 97 48
 Mobile spine 97 27 58 29
 Sacrum or Coccyx 111 31 42 21
 Othersb 4 1 5 2
Current status of disease
 Disease-free (no evidence of tumor) 145 41 38 19
 Stable local disease 101 28 43 21
 Progressive local disease 21 6 23 11
 Stable metastatic disease 17 5 7 3
 Progressive metastatic disease 25 7 17 8
 Not sure 28 8 7 3
Treatment received
 Surgery only 89 25 25 12
 Radiotherapy only 24 7 8 4
 Medical therapy only 3 1 0 0
 Multiple treatments 204 57 146 72
 No treatment reported 10 3 5 2
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combination of surgery, radiotherapy, or medical therapy 
(57%) followed by surgery only (25%) and radiotherapy 
only (7%). Table 2 shows the distribution of treatment types 
based on the anatomic site of chordoma tumor reported by 
chordoma patients.
Patient‑reported symptoms
The most common symptoms that chordoma patients 
reported include chronic pain (35%), depression or severe 
anxiety (32%), chronic fatigue (31%), difficulty walking 
(28%), and balance impairment (26%). The majority of 
patients in our sample reported experiencing at least one 
symptom (93%), while more than 36% experience 5 or 
more symptoms as a result of suffering from chordoma. 
Thirty patients (8%) did not respond to the question about 
symptoms.
The majority of self-reported symptoms were signifi-
cantly associated with the location of tumor (Table 3, last 
column). Among patients with skull base tumors (40%), the 
three most common symptoms were double vision (50%), 
depression or severe anxiety (32%), and chronic sinus 
Table 2  Distribution of treatment types based on the anatomic site of chordoma tumor reported by chordoma patients (n = 329)
Fisher’s exact test p = 0.004
a At least two treatment types from surgery, radiotherapy, or medical treatment categories
Tumor location All Treatment type
Surgery only (n = 88) Radiotherapy 
only (n = 24)
Medical treatment 
only (n = 3)
No treatment 
(n = 10)
Multiple 
 treatmentsa 
(n = 204)
Skull base 134 (56%) 22 (16%) 11 (8%) 0 (0%) 6 (4%) 95 (71%)
Mobile spine 91 (28%) 22 (24%) 7 (8%) 1 (1%) 2 (2%) 59 (65%)
Sacrum or Coccyx 100 (30%) 42 (42%) 6 (6%) 2 (2%) 2 (2%) 48 (48%)
Other 4 (1%) 2 (50%) 0 (0%) 0 (0%) 0 (0%) 2 (50%)
Table 3  Distribution of the patient-reported symptoms associated with chordoma by tumor location
Symptoms were asked using the following survey question: “Which of the following health effects have you ever suffered as a result of chor-
doma?”
a Includes neck, mid back, and lower back
b Includes extra-axial, multifocal, or unknown
c P-values were calculated using Fisher’s exact test
Symptom All (n = 327) 
(%)
Chordoma tumor location
Skull base 
(n = 131) (%)
Mobile  spinea 
(n = 92) (%)
Sacrum or Coccyx 
(n = 101) (%)
Otherb 
(n = 3) (%)
P-valuec
Chronic pain (n = 123) 38 14 57 51 33 0.001
Depression or severe anxiety (n = 113) 35 35 37 31 67 0.489
Chronic fatigue (n = 110) 34 30 39 33 67 0.269
Difficulty walking (n = 100) 31 7 40 54 67 0.001
Balance impairment (n = 94) 29 33 26 25 67 0.205
Difficulty sitting (n = 85) 26 2 20 62 33 0.001
Double vision (n = 76) 23 56 1 2 0 0.001
Sexual dysfunction (n = 74) 23 15 10 46 0 0.001
Limited mobility (n = 63) 19 3 33 29 0 0.001
Urinary incontinence (n = 52) 16 2 2 48 0 0.001
Chronic sinus problems (n = 46) 14 34 1 0 0 0.001
Urinary retention (n = 46) 14 1 3 42 0 0.001
Hearing loss (n = 44) 13 32 1 1 0 0.001
Fecal incontinence (n = 41) 13 0 1 40 0 0.001
Bowel obstruction (n = 38) 12 2 7 30 0 0.001
Other vision problems (n = 28) 9 16 3 4 0 0.002
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problems (31%). Among patients with sacral tumors (20%), 
difficulty sitting (55%), difficulty walking (53%), and sex-
ual dysfunction (49%) were the most common, and among 
patients with lower back tumor (11%), the most common 
symptoms were chronic pain (54%), difficulty walking 
(49%), and limited mobility (41%). Several common symp-
toms were significantly different in their prevalence across 
different types of treatment received and disease status 
(Tables 4, 5).
Challenges experienced by chordoma patients 
and caregivers
Table  6 reports the prevalence of challenges that patients 
and caregivers experienced as a result of chordoma in the 
following domains: emotional health and coping; employ-
ment and finances, access to care and information; and 
quality of care. Eight patients (2%) and four caregivers 
(2%) did not respond to the question about challenges faced 
as a result of suffering from chordoma. The most common 
challenges reported by patients were delayed care (37%), 
long-term disability (33%), confusion or unanswered ques-
tions about chordoma (28%), difficulty finding experienced 
physicians or treatment centers (27%), misdiagnosis (24%), 
and short-term disability (24%). Among caregivers, the 
most frequently reported challenges included grief (55%), 
delayed care (47%), difficulty helping the patient cope with 
his/her illness (45%), confusion or unanswered questions 
about chordoma (45%), difficulty finding experienced phy-
sicians or treatment centers (43%), and misdiagnosis of the 
patient (28%).
Discussion
Although several studies of chordoma symptoms and qual-
ity of life exist, they focus on a small number of cases, lim-
ited list of symptoms, or a specific tumor location or treat-
ment modality [2, 7, 13, 14]. This study adds to the existing 
literature by investigating self-reported symptom burden 
and life challenges among a large group of chordoma 
patients and caregivers across different tumor characteris-
tics. Our study data suggest high symptom burden among 
chordoma patients that varies based on the location of the 
tumor, disease status, and type of treatment received. In 
addition, our findings show that the chordoma patients and 
caregivers face many medical, emotional, and healthcare 
challenges. Receiving inappropriate care including but not 
limited to delayed diagnosis or misdiagnosis and difficulty 
finding experienced physicians or medical centers were 
among the most commonly cited challenges. Our study 
results provide a better understanding of the challenges 
Table 4  Distribution of the patient-reported symptoms associated with chordoma by treatment received
Symptoms were asked using the following survey question: “Which of the following health effects have you (the patient) ever suffered as a result 
of chordoma?”
a P-values were calculated using Fisher’s exact test
Symptom All 
(n = 322) 
(%)
Treatment received P-valuea
Surgery only 
(n = 87) (%)
Radiotherapy 
only (n = 22) 
(%)
Medical therapy 
only (n = 3) (%)
No treat-
ment (n = 8) 
(%)
Multiple ther-
apy (n = 202) 
(%)
Chronic pain (n = 122) 38 49 27 33 38 34 0.107
Depression or severe anxiety (n = 111) 34 38 27 67 38 33 0.632
Chronic fatigue (n = 106) 33 29 18 33 38 36 0.375
Difficulty walking (n = 97) 30 34 27 33 50 28 0.502
Balance impairment (n = 92) 29 22 23 33 38 32 0.394
Difficulty sitting (n = 82) 25 44 18 33 50 17 0.001
Double vision (n = 75) 23 13 32 33 25 27 0.046
Sexual dysfunction (n = 72) 22 26 27 33 13 20 0.607
Limited mobility (n = 62) 19 26 5 67 25 17 0.020
Urinary incontinence (n = 49) 15 15 9 67 38 14 0.059
Urinary retention (n = 46) 14 16 0 33 38 14 0.040
Chronic sinus problems (n = 45) 14 5 18 0 13 18 0.022
Hearing loss (n = 44) 14 6 18 33 13 16 0.050
Fecal incontinence (n = 40) 12 18 14 33 13 9 0.128
Bowel obstruction (n = 38) 12 15 9 67 13 10 0.075
Other vision problems (n = 25) 8 3 14 33 13 8 0.084
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associated with chordoma, with the aim of helping improve 
the quality of care provided to chordoma patients.
Our study also provides prevalence data for a com-
prehensive list of patient-reported symptoms as well as 
patient- and caregiver-reported life challenges associated 
with chordoma. These findings can inform the design of 
clinical trials and guide the development of chordoma-
specific PRO instruments or selection of existing generic 
instruments. Information about the prevalence of symptoms 
and life challenges is necessary for identifying which con-
cepts should be assessed. For detailed information about 
symptoms and life challenges specific to sacral chordoma 
patients and an example of using existing generic (non-
disease specific) PRO instruments to develop a compre-
hensive questionnaire, see van Wulfften Palthe et al. (2016) 
[14]. Because of the nature of the chordoma—in that the 
impact of the disease varies by the location of the tumor(s), 
instruments for specific types of chordoma may be war-
ranted, depending on the goals of the study. This could be 
operationalized as a series of independent tumor site-spe-
cific instruments or one instrument with tumor site-specific 
modules and branching logic. Further, our findings can 
be directly utilized in clinical practice. Information about 
prevalent symptoms and challenges faced by patients and 
caregivers may help improve patient–provider communica-
tion, inform decision-making, healthcare management, and 
ultimately improve health outcomes.
The major strengths of this study include its relatively 
large sample size of both chordoma patients and caregiv-
ers. Given the incidence and average survival of chordoma 
patients, the estimated prevalence is approximately 6 per 
million, or roughly 2,000 patients in the United States. 
Thus, the survey sample included more than 10% of the 
estimated United States chordoma patient population. In 
addition, the construction of the survey was patient-cen-
tered, and approximately 90% of respondents completed 
the entire questionnaire. However, we acknowledge the 
limitations associated with the online questionnaire admin-
istration. Our study sample included a high proportion of 
respondents with a university degree (65%), and was lim-
ited to those who have access to a computer, can read in 
English, and have the mental and physical capacity to com-
plete the online questionnaire. In addition, because patients 
and their caregivers had access to the survey questionnaire, 
Table 5  Distribution of the patient-reported symptoms associated with chordoma by disease status (n = 309)
Symptoms were asked using the following survey question: “Which of the following health effects have you (the patient) ever suffered as a result 
of chordoma?”
a P-values were calculated using Fisher’s exact test
Symptom All 
(n = 309) 
(%)
Current disease status P-valuea
Disease-free 
(n = 138) (%)
Stable local 
(n = 87) (%)
Progressive 
local (n = 18) 
(%)
Stable meta-
static (n = 17) 
(%)
Progressive 
metastatic 
(n = 24) (%)
Not sure 
(n = 25)
(%)
Chronic pain (n = 117) 38 39 29 44 41 58 36 0.157
Depression or 
severe anxiety
(n = 112) 36 37 37 39 35 33 32 0.997
Chronic fatigue (n = 103) 33 30 38 17 35 50 28 0.233
Difficulty walking (n = 92) 30 30 16 56 35 58 24 0.001
Balance impair-
ment
(n = 90) 29 22 34 33 29 38 36 0.290
Difficulty sitting (n = 76) 25 33 11 28 12 50 8 0.001
Double vision (n = 72) 23 17 39 28 12 17 16 0.004
Sexual dysfunction (n = 72) 23 22 14 33 53 38 20 0.006
Limited mobility (n = 62) 20 22 8 28 35 42 12 0.001
Urinary inconti-
nence
(n = 48) 16 20 4 17 12 38 12 0.001
Chronic sinus 
problems
(n = 44) 14 9 26 11 18 8 8 0.009
Urinary retention (n = 43) 14 20 6 6 18 17 12 0.051
Hearing loss (n = 41) 13 6 23 17 18 13 16 0.005
Fecal incontinence (n = 39) 13 17 4 17 12 21 12 0.021
Bowel obstruction (n = 36) 12 12 5 22 18 29 8 0.010
Other vision prob-
lems
(n = 27) 9 4 18 17 6 4 0 0.003
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for questions that could be answered both by patients and 
caregivers, it is possible that some responses are counted 
both from a patient and his or her caregiver. Nonetheless, 
the distribution of age and tumor location in our sample 
is similar to that reported in the literature from the repre-
sentative population-based estimates [1–3]. Although this 
survey included a large proportion (10%) of the US chor-
doma patient population, because of the sampling scheme 
that was employed in this study, the denominator is not 
clearly defined and the sample underrepresents population 
subgroups who may experience the challenges of chordoma 
differently. Therefore, the results of this study are limited 
preliminary estimates intended to be hypothesis generating 
and to inform future research.
Previous studies have estimated quality of life in specific 
subgroups of chordoma patients using validated, non-dis-
ease specific instruments, such as the 36-Item Short Form 
Health Survey (SF-36) and the European Organization for 
Research and Treatment of Cancer Quality of Life Core 
30 (EORTC QLQ-C30) [2, 13]. However, the intent of the 
CF survey was not to estimate the quality of life scores 
for the study sample. Instead, the survey questionnaire 
was designed to document the prevalence of a wide range 
of symptoms and challenges experienced by chordoma 
patients and caregivers. The content was determined based 
on input from members of the chordoma patient commu-
nity, the moderators of the chordoma survivors Facebook 
group, and physicians who treat chordoma patients, and 
the questionnaire included open-ended response fields for 
each response option of “other” to elicit any additional 
symptoms and issues. The CF survey was able to capture 
symptoms and challenges specific to chordoma that were 
not reflected in the more general quality of life measures 
used previously.
Table 6  Challenges that 
patients/caregivers face as a 
result of having/caring for a 
patient with chordoma
The challenges were asked in the following questions in the survey: “Which of the following challenges 
have you faced as a result of your experience with chordoma?” and “Which of the following challenges 
have you faced in caring for someone with chordoma?”
a Response option only available to respondents who identify themselves as caregivers of chordoma 
patients
b Response option only available to respondents who identify themselves as patients
Patients 
(n = 358)
Caregivers 
(n = 202)
No. Percent No. Percent
Emotional health and coping
 Feelings of loneliness or isolation 104 29 87 43
 Difficulty coping/helping the patient cope with his/her illness 93 26 91 45
 Griefa – – 111 55
 Family conflict 34 10 46 23
 Difficulty helping children or other family members cope 47 13 67 33
 Difficulty talking about chordoma and how it has affected my life 64 18 43 21
Employment and finances
 Change in career or reduced ability to work 118 33 63 31
 Short-term  disabilityb 84 24 – –
 Long-term  disabilityb 119 33 – –
 Loss of employment 74 21 20 10
 Financial distress (including bankruptcy or foreclosure) 59 17 39 19
Access to care and information
 Denial of insurance coverage for the patient’s recommended treatment 45 13 34 17
 Loss of health  insuranceb 20 6 – –
 Inability to pay for the patient’s recommended treatment 28 8 20 10
 Inability to pay for travel, lodging, or other treatment-related expenses 45 13 28 14
 Confusion or unanswered questions about chordoma 101 28 90 45
 Difficulty finding experienced physicians or treatment centers 96 27 86 43
Quality of care
 Delayed diagnosis of patient 134 37 95 47
 Misdiagnosis of patient 85 24 56 28
 Difficulty dealing with physicians or medical staff 77 22 50 25
 Patient received wrong or inappropriate care 64 18 49 24
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Conclusion
Our study findings suggest a high symptom burden among 
patients with chordoma. In addition, many patients and 
caregivers are facing challenges related to access and qual-
ity of care and psychological health. This study provides 
preliminary, limited estimates of the prevalence of a wide 
range of self-reported symptoms and challenges that will 
inform the assessment of patient-reported outcomes in 
future clinical trials and will help clinicians and palliative 
care providers better understand and manage symptoms of 
chordoma patients.
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